EUVIMEDEUVIMED entdecken
Open Access

Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin

Randall J Smith, Robert Zollo, Sukumar Kalvapudi, Yeshwanth Vedire, Akhil Goud Pachimatla, Cara Petrucci, Garrison Shaller, Deschana Washington iD, Vethanayagam Rr, Stephanie N Sass, Aravind Srinivasan, Eric Kannisto und 5 weitere

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djae295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Randall J Smith und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States. Hauptthemen laut MEDLINE: Metformin, Lung Neoplasms, Obesity, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, CCSG, American Lung Association Lung Cancer Discovery.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preclinical cancer studies ascribe promising anticancer properties to metformin. Yet, clinical findings vary, casting uncertainty on its therapeutic value for non–small cell lung cancer (NSCLC) patients. We hypothesized that metformin could benefit obese and overweight patients with NSCLC.

Methods

We retrospectively analyzed 2 clinical cohorts and employed complementary mouse models to test our hypothesis. One cohort included NSCLC patients with overweight body mass index (≥25 kg/m2, n = 511) and nonoverweight body mass index (<25 kg/m2, n = 232) who underwent lobectomy, evaluating metformin’s impact on clinical outcomes. Another cohort examined metformin’s effect on progression-free survival after immune checkpoint inhibitors in overweight (n = 284) vs nonoverweight (n = 184) NSCLC patients. Metformin’s effects on tumor progression, antitumor immunity, and immune checkpoint inhibitor response in obese and normal-weight mice were assessed with lung cancer models.

Results

Metformin is associated with increased recurrence-free survival in overweight patients (hazard ratio [HR] = 0.47, 95% confidence interval [CI] = 0.24 to 0.94; P = .035) after lobectomy. It also corrected accelerated tumor growth in diet-induced obese mouse models in a lymphocyte-specific manner while reversing several mechanisms of immune suppression potentiated by obesity. Programmed cell death 1 blockade coupled with metformin was more effective at limiting tumor burden in obese mice and correlated with progression-free survival only in overweight patients on immunotherapy (HR = 0.60, 95% CI = 0.39 to 0.93; P = .024).

Conclusions

Metformin may improve lung cancer–specific clinical outcomes in obese and overweight lung cancer patients and enhance immunotherapy efficacy in this growing population. This work identifies obesity as a potential predictive biomarker of metformin’s anticancer and immunotherapy-enhancing properties in lung cancer while shedding light on the underlying immunological phenomena.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminLung NeoplasmsObesityCarcinoma, Non-Small-Cell LungImmunotherapyHumansFemaleMaleAnimalsMiceRetrospective StudiesMiddle AgedAgedImmune Checkpoint InhibitorsTreatment OutcomeBody Mass IndexOverweightProgression-Free Survival

Substanzen

MetforminImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States.
  • Department of Thoracic Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States.
  • Department of Medicine, University at Buffalo, State University of New York, Buffalo, NY 14263, United States.
  • Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States.
  • Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States.

ORCID-Profile: Deschana Washington, Sai Yendamuri

Förderung

  • NCI NIH HHS
  • CCSG
  • American Lung Association Lung Cancer Discovery
  • NIGMS NIH HHS
  • National Cancer Institute

Zitieren

APA

Smith, R. J., Zollo, R., Kalvapudi, S., Vedire, Y., Pachimatla, A. G., Petrucci, C., Shaller, G., Washington, D., Rr, V., Sass, S. N., Srinivasan, A., Kannisto, E., Bawek, S., Jain, P., Rosario, S., Barbi, J., & Yendamuri, S. (2025). Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae295

Vancouver

Smith RJ, Zollo R, Kalvapudi S, Vedire Y, Pachimatla AG, Petrucci C, et al. Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae295

BibTeX
@article{Smith2025,
  author = {Smith, Randall J and Zollo, Robert and Kalvapudi, Sukumar and Vedire, Yeshwanth and Pachimatla, Akhil Goud and Petrucci, Cara and Shaller, Garrison and Washington, Deschana and Rr, Vethanayagam and Sass, Stephanie N and Srinivasan, Aravind and Kannisto, Eric and Bawek, Sawyer and Jain, Prantesh and Rosario, Spencer and Barbi, Joseph and Yendamuri, Sai},
  title = {Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djae295}
}
Kostenlos starten →